Pomerantz Law Firm Investigates Claims on Behalf of Investors of Seracare Life Sciences, Inc.
29 Febrero 2012 - 4:00PM
Business Wire
Pomerantz Haudek Grossman & Gross LLP is investigating
claims on behalf of investors of SeraCare Life Sciences (“SeraCare”
or the “Company”) (NASDAQ: SRLS) (ISIN: US81747T1043) concerning
the proposed acquisition of SeraCare by Linden Capital Partners
(“Linden”) in a cash transaction valued at approximately $82
million.
The investigation concerns whether the SeraCare directors are
breaching their fiduciary duties by failing to adequately shop the
Company and maximize shareholder value. Under the terms of the
agreement, SeraCare shareholders would receive $4.00 in cash per
share of SeraCare common stock. However, SeraCare has traded above
$4.00 per share and at least one analyst has set a target price of
$5.00 per share.
SeraCare shareholders seeking more information about this
acquisition are advised to contact Gustavo Bruckner, Esq. at
gfbruckner@pomlaw.com or 212-661-1100 or toll free at 888-476-6529,
ext. 302. Shareholders may also contact Rebecca Jarmon at
rjarmon@pomlaw.com or 212-661-1100 or 888-476-6529, ext. 314.
The Pomerantz Firm, with offices in New York, Chicago, and
Washington, D.C., is acknowledged as one of the premier firms in
the areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L. Pomerantz, known as the dean of the
class action bar, the Pomerantz Firm pioneered the field of
securities class actions. Today, more than 70 years later, the
Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of
fiduciary duty, and corporate misconduct. The Firm has recovered
numerous multimillion-dollar damages awards on behalf of class
members. See www.pomerantzlaw.com.
Seracare Life Sciences (NASDAQ:SRLS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Seracare Life Sciences (NASDAQ:SRLS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Seracare Life Sciences (MM) (NASDAQ): 0 recent articles
Más de Pomerantz Haudek Grossman & Gross LLP Artículos de Noticias